High-level results from the OSTRO Phase III trial showed AstraZeneca plc (LON:AZN) Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in..

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal..

AstraZeneca plc (LON:AZN) has confirmed that the first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose..

AstraZeneca plc (LON:AZN) Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common..

AstraZeneca plc (LON:AZN) Breztri Aerosphere has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and..

AstraZeneca plc (LON:AZN) has announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Brilinta for the reduction of subsequent stroke..

AstraZeneca plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) have announced that Lynparza has been approved in the European..

AstraZeneca plc (LON:AZN) has announced that selumetinib has been granted orphan drug designation in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.1 Selumetinib..

AstraZeneca plc (LON:AZN) has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the..

AstraZeneca PLC (LON:AZN) Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD),..

Detailed results from the Phase III ADAURA trial showed AstraZeneca PLC (LON:AZN) Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival in the adjuvant treatment of patients..

AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company Limited’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation in the US for the treatment of patients with gastric cancer, including gastroesophageal junction..

AstraZeneca PLC (LON:AZN) is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s..

AstraZeneca PLC (LON:AZN) and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in the US for patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer...

AstraZeneca PLC (LON:AZN) Bevespi Aeroshere (glycopyronium/formoteral fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis..

AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or..

AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced..

AstraZeneca PLC (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results from the Phase III..

AstraZeneca plc (LON:AZN) ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung..